Shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) have been given a consensus recommendation of “Hold” by the eight brokerages that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $26.20.

A number of equities analysts have issued reports on the company. Wells Fargo & Company reiterated an “outperform” rating and set a $31.00 price target on shares of Bellicum Pharmaceuticals in a research note on Tuesday, June 27th. Cantor Fitzgerald reiterated an “overweight” rating and set a $35.00 price target on shares of Bellicum Pharmaceuticals in a research note on Monday, June 26th. Ladenburg Thalmann Financial Services set a $31.00 price target on Bellicum Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, June 24th. Raymond James Financial, Inc. reiterated a “buy” rating on shares of Bellicum Pharmaceuticals in a research note on Tuesday, June 27th. Finally, Jefferies Group LLC cut their price target on Bellicum Pharmaceuticals from $19.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, May 9th.

Shares of Bellicum Pharmaceuticals (NASDAQ:BLCM) opened at 7.52 on Tuesday. The company’s 50-day moving average price is $11.21 and its 200 day moving average price is $12.28. The company’s market cap is $249.86 million. Bellicum Pharmaceuticals has a 12-month low of $7.41 and a 12-month high of $23.11.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by $0.09. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 70.74%. During the same period last year, the company posted ($0.61) EPS. Equities analysts predict that Bellicum Pharmaceuticals will post ($3.00) earnings per share for the current year.

In other Bellicum Pharmaceuticals news, VP Ken Moseley sold 13,823 shares of Bellicum Pharmaceuticals stock in a transaction that occurred on Thursday, July 13th. The shares were sold at an average price of $12.26, for a total transaction of $169,469.98. Following the transaction, the vice president now owns 14,314 shares of the company’s stock, valued at approximately $175,489.64. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Alan A. Musso sold 6,311 shares of Bellicum Pharmaceuticals stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $12.24, for a total transaction of $77,246.64. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,571 shares of company stock worth $367,295. Insiders own 23.30% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Ronald Blue & Co. LLC purchased a new position in Bellicum Pharmaceuticals during the second quarter valued at approximately $117,000. Clear Harbor Asset Management LLC purchased a new position in Bellicum Pharmaceuticals during the second quarter valued at approximately $118,000. Knott David M purchased a new position in Bellicum Pharmaceuticals during the first quarter valued at approximately $131,000. Voya Investment Management LLC purchased a new position in Bellicum Pharmaceuticals during the second quarter valued at approximately $132,000. Finally, Eagle Ridge Investment Management purchased a new position in Bellicum Pharmaceuticals during the first quarter valued at approximately $144,000. 63.97% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This article was posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/bellicum-pharmaceuticals-inc-blcm-receives-average-recommendation-of-hold-from-brokerages/1489420.html.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Analyst Recommendations for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.